Skip to main content
Fig. 1 | Cardiovascular Diabetology

Fig. 1

From: Clinical potential of inclisiran for patients with a high risk of atherosclerotic cardiovascular disease

Fig. 1

The role of PCSK9 in lipid metabolism. LDLRs on the surface of the liver cells bind circulating LDL, and LDL/LDLR complexes are internalized via clathrin‐mediated endocytosis. LDL is released for degradation in the lysosome, while the LDLR is recycled to the cell surface. In extracellular pathway, PCSK9 binds to the LDLR on the surface of the liver cell and then internalizes with LDLR to intracellular degradation in the lysosome, which increase serum LDL levels by preventing LDLR recycling to the membrane. In intracellular pathway, the secreted PCSK9 from Golgi apparatus can be sorted directly to lysosomes as a PCSK9–LDLR complex, leading to intracellular degradation of the LDLR. LDLR LDL receptors, PCSK9 proprotein convertase subtilisin/kexin type 9

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840